Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable non–small cell lung cancer: How do I choose? Importance of immune biomarkers and molecular testing

Central Picture legend: Phase 3 Immunotherapy trials in resectable NSCLC (completed and reported to date) Central Message: Although neoadjuvant, perioperative, or adjuvant immunotherapy are all acceptable standards of care in resectable NSCLC, there is supportive data suggesting superiority of perioperative immunotherapy.